Day One Biopharmaceuticals, Inc.
DAWNDelisted Apr 23, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001845337
Day One Biopharmaceuticals, Inc. was delisted on Apr 23, 2026; its insiders filed their last Form 4 on Apr 27, 2026; 208 institutions reported holding it in 13F filings for Q1 2026, worth $1.85B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Day One Biopharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Day One Biopharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Blavatnik Len | 10% Owner | 0 | Apr 27, 2026 | 1 |
| Access Industries Holdings LLC | 10% Owner | 0 | Apr 27, 2026 | 1 |
| Access Industries Management, LLC | 10% Owner | 0 | Apr 27, 2026 | 1 |
| AI Day1 LLC | 10% Owner | 0 | Apr 27, 2026 | 1 |
| Garland J. Scott | Director | – | Apr 23, 2026 | 2 |
| Ramasastry Saira | Director | 0 | Apr 23, 2026 | 2 |
| Holles Natalie C. | Director | 0 | Apr 23, 2026 | 2 |
| Nicholson Garry A | Director | – | Apr 23, 2026 | 2 |
| York Charles N II | COO and CFO | 0 | Apr 23, 2026 | 5 |
| Dable Habib J | Director | – | Apr 23, 2026 | 2 |
| Grossman William | Director | – | Apr 23, 2026 | 2 |
| Vasconcelles Michael | Head of Research and Dev. | 0 | Apr 23, 2026 | 3 |
| Dubow Adam | Gen Counsel & Secretary | 0 | Apr 23, 2026 | 5 |
| Josey John A. | Director | 0 | Apr 23, 2026 | 2 |
| Merendino Lauren | Chief Commercial Officer | 0 | Apr 23, 2026 | 5 |
| Bender Jeremy | CHIEF EXECUTIVE OFFICER | 0Indirect | Apr 23, 2026 | 6 |
| Blackman Samuel C. | HEAD OF R&D | 1,034,015 | Dec 12, 2024 | 0 |
| Gladstone Michael | Director | 766,667Indirect | May 28, 2024 | 0 |
| Becker Daniel J. | Director | – | Jun 26, 2023 | 0 |
| Grant Papanek Julie | Director | 330,000Indirect | Mar 3, 2023 | 0 |
| Atlas Venture Fund XI, L.P. | 10% Owner | 6,008,534 | Dec 14, 2022 | 0 |
| Canaan XI L.P. | 10% Owner | 6,964,301 | Sep 22, 2022 | 0 |
| Canaan Partners XI LLC | 10% Owner | 6,964,301 | Sep 22, 2022 | 0 |
| Atlas Venture Opportunity Fund I, L.P. | 10% Owner | 793,116 | Jul 6, 2022 | 0 |
| Atlas Venture Associates Opportunity I, L.P. | 10% Owner | 766,667 | Jun 22, 2022 | 0 |
| Atlas Venture Associates Opportunity I, LLC | 10% Owner | 766,667 | Jun 22, 2022 | 0 |
| Atlas Venture Associates XI, LLC | 10% Owner | 766,667 | Jun 22, 2022 | 0 |
| Atlas Venture Associates XI, L.P. | 10% Owner | 766,667 | Jun 22, 2022 | 0 |
| Atlas Venture Opportunity Fund II, L.P. | 10% Owner | 766,667 | Jun 22, 2022 | 0 |
| Millennium Pharmaceuticals Inc | 10% Owner | 6,120,124Indirect | Dec 9, 2021 | 0 |
| Takeda Pharmaceutical Co Ltd | 10% Owner | 6,120,124Indirect | Dec 9, 2021 | 0 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10% Owner | 6,120,124Indirect | Dec 9, 2021 | 0 |
| Takeda Ventures, Inc. | 10% Owner | 6,120,124Indirect | Dec 9, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2022 (view filing)7:48 PM ET | Sep 13-15 | 2 days | Canaan XI L.P. and 1 other10% Owner | SSale | −245.0K | $23.76 | −$5.82M | −2.5%9.42M after | 6 lotsDuplicate filing |
| Sep 15, 2022 (view filing) | Sep 2 | 13 daysLate | Grant Papanek JulieDirector | SSale | −5.00K | $23.82 | −$119.1K | −1.1%439.4K after | |
| Sep 15, 2022 (view filing) | Sep 13-15 | 2 days | Grant Papanek JulieDirector | SSale | −245.0K | $23.76 | −$5.82M | −2.5%9.42M after | 6 lots |
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | York Charles N IICOO, CFO and Secretary | SSale | −10.0K | $23.25 | −$232.5K | −3.1%314.4K after | 2 lots |
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Grant Papanek JulieDirector | SSale | −5.00K | $23.27 | −$116.4K | −1.1%444.4K after | 2 lots |
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Blackman Samuel C.Chief Medical Officer | SSale | −10.0K | $23.24 | −$232.4K | −0.8%1.29M after | 2 lots |
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Bender JeremyChief Executive Officer | SSale | −12.5K | $23.25 | −$290.6K | −1.0%1.24M after | 2 lotsDuplicate filing |
| Sep 6, 2022 (view filing) | Sep 1 | 5 days | Bender JeremyChief Executive Officer | SSale | −12.5K | $23.25 | −$290.6K | −1.0%1.24M after | 2 lots |
| Aug 17, 2022 (view filing) | Aug 16 | 1 day | Blackman Samuel C.Chief Medical Officer | SSale | −941 | $24.31 | −$22.9K | −0.1%1.30M after | |
| Aug 17, 2022 (view filing) | Aug 16 | 1 day | Bender JeremyChief Executive Officer | SSale | −4.00K | $24.31 | −$97.3K | −0.3%1.25M after | |
| Aug 17, 2022 (view filing) | Aug 16 | 1 day | York Charles N IICOO, CFO and Secretary | SSale | −1.09K | $24.31 | −$26.5K | −0.3%324.4K after | |
| Aug 8, 2022 (view filing) | Aug 4-5 | 4 days | Grant Papanek JulieDirector | SSale | −10.0K | $20.00 | −$200.0K | −2.2%449.4K after | 2 lots |
| Aug 5, 2022 (view filing) | Aug 4 | 1 day | York Charles N IICOO, CFO and Secretary | SSale | −10.0K | $20.05 | −$200.5K | −3.0%321.4K after | |
| Aug 5, 2022 (view filing) | Aug 4 | 1 day | Bender JeremyChief Executive Officer | SSale | −12.5K | $20.00 | −$250.0K | −1.0%1.25M after | |
| Aug 3, 2022 (view filing) | Aug 1 | 2 days | Blackman Samuel C.Chief Medical Officer | SSale | −10.0K | $16.88 | −$168.8K | −0.8%1.30M after | |
| Jul 20, 2022 (view filing) | Jul 18 | 2 days | York Charles N IICOO, CFO and Secretary | SSale | −2.50K | $20.00 | −$50.0K | −0.7%331.4K after | |
| Jul 20, 2022 (view filing) | Jul 18 | 2 days | Grant Papanek JulieDirector | SSale | −2.60K | $20.00 | −$52.0K | −0.6%459.4K after | |
| Jul 20, 2022 (view filing) | Jul 18 | 2 days | Bender JeremyChief Executive Officer | SSale | −2.60K | $20.00 | −$52.0K | −0.2%1.26M after | |
| Jul 12, 2022 (view filing) | Jul 1-5 | 11 days | Grant Papanek JulieDirector | SSale | −1.80K | $20.00 | −$36.0K | −0.4%463.2K after | Amended2 lots |
| Jul 12, 2022 (view filing) | Jul 8 | 4 days | Grant Papanek JulieDirector | SSale | −1.24K | $20.00 | −$24.8K | −0.3%462.0K after | |
| Jul 12, 2022 (view filing) | Jul 8 | 4 days | York Charles N IICOO, CFO and Secretary | SSale | −1.42K | $20.00 | −$28.3K | −0.4%333.9K after | |
| Jul 12, 2022 (view filing) | Jul 8 | 4 days | Bender JeremyChief Executive Officer | SSale | −1.79K | $20.00 | −$35.9K | −0.1%1.26M after | |
| Jul 6, 2022 (view filing) | Jul 1-5 | 5 days | York Charles N IICOO, CFO and Secretary | SSale | −2.28K | $20.00 | −$45.6K | −0.7%335.3K after | 2 lots |
| Jul 6, 2022 (view filing) | Jul 1 | 5 days | Blackman Samuel C.Chief Medical Officer | SSale | −10.0K | $18.72 | −$187.2K | −0.8%1.31M after | 3 lots |
| Jul 6, 2022 (view filing) | Jul 1-5 | 5 days | Bender JeremyChief Executive Officer | SSale | −2.60K | $20.00 | −$52.1K | −0.2%1.26M after | 2 lots |
| Jun 22, 2022 (view filing)5:09 PM ET | Jun 17 | 5 days | Atlas Venture Fund XI, L.P. and 6 others10% Owner | PPurchase | +766.7K | $15.00 | +$11.5M | New position766.7K after | Duplicate filing |
| Jun 22, 2022 (view filing) | Jun 17 | 5 days | Gladstone MichaelDirector | PPurchase | +766.7K | $15.00 | +$11.5M | New position766.7K after | |
| Jun 21, 2022 (view filing)4:37 PM ET | Jun 17 | 4 days | Blavatnik Len and 3 othersOther: Affiliate of 10% Owner | PPurchase | +1.20M | $15.00 | +$18.0M | +12.7%10.7M after | |
| Jun 17, 2022 (view filing) | Jun 15 | 2 days | Blackman Samuel C.Chief Medical Officer | SSale | −50.0K | $16.26 | −$813.0K | −3.7%1.32M after | |
| Jan 20, 2022 (view filing)6:37 PM ET | Jan 18-20 | 2 days | Blavatnik Len and 3 othersOther: Affiliate of 10% Owner | PPurchase | +106.9K | $14.52 | +$1.55M | +1.1%9.48M after | 3 lots |
| Jan 5, 2022 (view filing) | Jan 3 | 2 days | Blackman Samuel C.Chief Medical Officer | SSale | −10.0K | $17.10 | −$171.0K | −0.7%1.37M after | 2 lots |
| Dec 9, 2021 (view filing)6:04 AM ET | Dec 7-8 | 2 days | Millennium Pharmaceuticals Inc and 3 others10% Owner | SSale | −297.3K | $18.49 | −$5.50M | −4.6%6.12M after | 3 lots |
| Dec 7, 2021 (view filing)6:01 AM ET | Dec 3-6 | 4 days | Millennium Pharmaceuticals Inc and 3 others10% Owner | SSale | −110.2K | $18.10 | −$1.99M | −1.7%6.42M after | 2 lots |
| Dec 3, 2021 (view filing) | Dec 1 | 2 days | Blackman Samuel C.Chief Medical Officer | SSale | −10.0K | $17.22 | −$172.2K | −0.7%1.38M after | 3 lots |